Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia

Robert J. Kreitman*, Martin S. Tallman, Tadeusz Robak, Steven Coutre, Wyndham H. Wilson, Maryalice Stetler-Stevenson, David J. FitzGerald, Robert Lechleider, Ira Pastan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

264 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

INIS